RECEIVED
CENTRAL FAX CENTER
DEC 14 2006

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim1 (currently amended) A compound having the chemical formula:



wherein:

R^1, R^2 and R^3 is each independently chosen from: H, halogen, CN, CF_3, OCF_3, lower alkyl, lower alkoxy, NH-acetyl, NH-lower alkyl, NH-alkylaryl, N(lower alkyl)$_2$, C(O)OH, C(O)O-lower alkyl, C(O)NH-lower alkyl, C(O)N(lower alkyl)$_2$, OH, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-N(lower alkyl)$_2$, and OP(O)(OH)$_2$;

~~X^1 is chosen from: C and N, such that when X^1 is C then~~ R^4 is chosen from: H, halogen, CN, CF_3, OCF_3, lower alkyl, lower alkoxy, NH-acetyl, NH-lower alkyl, NH-alkylaryl, N(lower alkyl)$_2$, C(O)OH, C(O)O-lower alkyl, C(O)NH-lower alkyl, C(O)N(lower alkyl)$_2$, OH, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-N(lower alkyl)$_2$, and OP(O)(OH)$_2$;

X^1 is selected from one of C and N, such that when X^1 is N, then R^4 is absent;

R^5 is chosen from: H, a thienyl, styryl, pyridyl and phenyl group, wherein the thienyl, styryl, pyridyl and phenyl group is optionally substituted with 1 to 3 substituents chosen from: H, halogen, CN, CF_3, OCF_3, lower alkyl, NH-alkylaryl, N(lower alkyl)$_2$, OH, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-NH-lower alkyl, OC(O)-lower alkyl-N(lower alkyl)$_2$, and OP(O)(OH)$_2$;

R^6 comprises $-(CH_2)_n-X^2-R^7$ wherein n is 1 or 2, X^2 is O, C(O), CH(OH), lower alkyl or a single bond, and

R^7 is chosen from a pyridyl and a phenyl group, wherein R^7 is optionally substituted with 1 to 3 substituents chosen from: H, halogen, CN, OCF_3, unsubstituted lower alkyl, NH-alkylaryl, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-N(lower alkyl)$_2$, and $OP(O)(OH)_2$;

or a pharmaceutically acceptable salt or complex thereof;

wherein the compound has a Calcium Receptor Inhibitor Assay IC_{50} value of 30 μM or lower.

Claim 2 (original) A compound according to claim 1, wherein R^1, R^2, R^3, and R^4 are independently selected from one of hydrogen, halogen, lower alkyl, OH and $OP(O)(OH)_2$.

Claim 3 (original) A compound according to claim 2, wherein said halogen is selected from one of fluorine and chlorine.

Claim 4 (original) A compound according to claim 2, wherein lower alkyl is methyl.

Claim 5 (original) A compound according to claim 2 wherein, R^1 is selected from one of hydrogen and methyl.

Claim 6 (original) A compound according to claim 2, wherein R^2 is selected from one of hydrogen, fluorine, chlorine, hydroxy, and methyl.

Claim 7 (original) A compound according to claim 2, wherein R^3 is selected from one of hydrogen and chlorine.

Claim 8 (original) A compound according to claim 2, wherein R^4 is selected from one of hydrogen, hydroxy, and methyl.

Claim 9 (original) A compound according to claim 1, wherein X^1 is carbon.

Claim 10 (original) A compound according to claim 1, wherein R^5 is phenyl optionally substituted with 1 or 2 hydroxy.

Claim 11 (original) A compound according to claim 1, wherein R^6 further comprises the group $-(CH_2)_n-X^2-R^7$;

wherein n is 1 or 2;

X^2 is a single bond, and

R^7 is phenyl optionally substituted with 1 or 2 halogens.

Claim 12 (original) A compound according to claim 11, wherein n is 2 and said halogens are selected from one of fluorine and chlorine.

Claim 13 (original) A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable diluent or excipient.

Claim 14 (currently amended) A method of treating a disease or disorder characterized by abnormal bone or mineral homeostasis chosen from: osteosarcoma, periodontal disease, fracture healing, osteoathritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis, ~~which is treatable by increasing serum parathyroid hormone levels,~~ comprising the administration to a subject in need of treatment thereof an effective amount of a compound according to claim 1.

Claim 15 (cancelled)

Claim 16 (original) A method according to claim 14, wherein the bone or mineral disease or disorder is osteoporosis.

Claim 17 (currently amended) A method of increasing serum parathyroid hormone levels in mammals for treatment of a disease or disorder chosen from: osteosarcoma, periodontal disease, fracture healing, osteoathritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis, which comprises the administration to a subject which may be benefited thereby an effective amount of a compound according to claim 1 sufficient to increase serum parathyroid hormone levels.

Claim 18 (original) A method for preparing 2,3,5,6,7,8-substituted 3*H*-quinazolin-4-ones by reacting 2,4,5,6,7,8-substituted benzo[*d*][1,3]oxazin-4-ones with primary amines under microwave irradiation conditions.

Claim 19 (currently amended) A compound selected from one of:
2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
2-(2,5-dihydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
2-(3-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
2-(2-hydroxy-phenyl)-3-(2-phenoxy-ethyl)-3*H*-quinazolin-4-one;
3-[2-(4-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
3-[2-(3-chloro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
3-[2-(2-chloro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
~~2-(2-hydroxy-phenyl)-3-[2-(4-methoxy-phenyl)-ethyl]-3*H*-quinazolin-4-one;~~
2-(2-hydroxy-phenyl)-3-[2-(2-methoxy-phenyl)-ethyl]-3*H*-quinazolin-4-one;
2-(2-hydroxy-phenyl)-3-(2-*p*-tolyl-ethyl)-3*H*-quinazolin-4-one;
2-(2-hydroxy-phenyl)-6-methyl-3-phenethyl-3*H*-quinazolin-4-one;

6-fluoro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;

6-chloro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;

2-(2-hydroxy-phenyl)-3-phenethyl-5-phenethylamino-3*H*-quinazolin-4-one;

2-(2-hydroxy-phenyl)-5-methyl-3-phenethyl-3*H*-quinazolin-4-one;

7-chloro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;

2-(2-hydroxy-phenyl)-8-methyl-3-phenethyl-3*H*-quinazolin-4-one;

6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

6-fluoro-3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

7-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-5-methyl-3*H*-quinazolin-4-one;

3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-5-methyl-3*H*-quinazolin-4-one;

3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-6-methyl-3*H*-quinazolin-4-one;

3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-6-methyl-3*H*-quinazolin-4-one;

6-chloro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

6-chloro-3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-6-methoxy-3*H*-quinazolin-4-one;

3-[2-(3-fluoro-phenyl)-ethyl]-6-hydroxy-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

acetic acid 2-{6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-4-oxo-3,4-dihydro-quinazolin-2-yl}-phenyl ester;

3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-8-methoxy-3*H*-quinazolin-4-one;

isobutyric acid 2-{6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-4-oxo-3,4-dihydro-quinazolin-2-yl}-phenyl ester;

sodium salt of 6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

8-chloro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;

7-chloro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

7-chloro-3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

2-(2-hydroxy-phenyl)-3-(2-pyridin-3-yl-ethyl)-3*H*-quinazolin-4-one;

6-fluoro-2-(2-hydroxy-phenyl)-3-(2-pyridin-3-yl-ethyl)-3*H*-quinazolin-4-one;

2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-pyrido[2,3-*d*]pyrimidin-4-one;

3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-pyrido[2,3-*d*]pyrimidin-4-one;

3-(1,1-dimethyl-3-phenyl-propyl)-6-fluoro-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;

methylamino-acetic acid 2-{6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-4-oxo-3,4-dihydro-quinazolin-2-yl}-phenyl ester hydrochloride;

6-fluoro-2-(2-hydroxy-phenyl)-3-(2-phenyl-propyl)-3*H*-quinazolin-4-one;

6-fluoro-2-(2-hydroxy-phenyl)-3-(*R*-2-phenyl-propyl)-3*H*-quinazolin-4-one;

6-fluoro-2-(2-hydroxy-phenyl)-3-(*S*-2-phenyl-propyl)-3*H*-quinazolin-4-one; and

6-fluoro-2-(2-hydroxy-phenyl)-3-(3-phenyl-propyl)-3*H*-quinazolin-4-one

or a pharmaceutically acceptable salt or complex thereof.